How to Get Retatrutide in South Carolina

What Is Retatrutide and Why Is It Generating Attention?

Retatrutide is a first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. Eli Lilly developed the molecule as a once-weekly subcutaneous injection for chronic weight management and type 2 diabetes. The drug remains investigational and has not received FDA approval as of May 2026.

How Retatrutide Differs from Other GLP-1 Drugs

Most approved anti-obesity medications target one or two receptors. Semaglutide (Wegovy) acts on GLP-1 alone. Tirzepatide (Zepbound) targets GIP and GLP-1. Retatrutide adds a third mechanism by also activating the glucagon receptor, which increases energy expenditure and hepatic fat oxidation [1]. This triple-agonist approach produced weight loss results in early trials that exceeded those of any currently approved medication in the same class.

Phase 2 Trial Results

In a 48-week phase 2 trial published in the New England Journal of Medicine, Jastreboff et al. Randomized 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity to retatrutide or placebo [1]. Participants receiving the highest dose (12 mg) achieved a mean body weight reduction of 24.2%, compared to 2.1% in the placebo group. The 8 mg group lost 22.8% of body weight. Gastrointestinal side effects (nausea, diarrhea, vomiting) were the most common adverse events and were mostly mild to moderate in severity [1].

Those numbers matter because they surpass the 15.7% mean weight loss seen with tirzepatide 15 mg at 72 weeks in the SURMOUNT-1 trial (N=2,539) [2] and the 14.9% with semaglutide 2.4 mg at 68 weeks in STEP-1 (N=1,961) [3]. Phase 3 trials are ongoing.

South Carolina Telehealth Rules for Retatrutide Prescribing

South Carolina permits telehealth prescribing for medications including compounded retatrutide. The South Carolina Board of Medical Examiners requires that a prescriber hold an active license in the state and establish a valid provider-patient relationship before writing a prescription [4]. This relationship can be established via a synchronous video or audio visit.

Who Can Prescribe

Three categories of licensed clinicians in South Carolina can prescribe retatrutide:

• Physicians (MD/DO): Full prescriptive authority. No collaborative agreement needed for weight management prescribing.
• Nurse Practitioners (NP): Can prescribe under their scope of practice in South Carolina. NPs with APRN certification may prescribe scheduled and non-scheduled medications.
• Physician Assistants (PA): Prescribe under a supervisory agreement with a licensed physician. The supervising physician does not need to be physically present during the telehealth visit.

What the Telehealth Visit Involves

A typical initial telehealth appointment for retatrutide lasts 15 to 30 minutes. The prescriber will review your medical history, current medications, BMI, and weight-related conditions. Expect questions about prior GLP-1 or anti-obesity medication use, cardiovascular history, and a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

The clinician will order baseline labs before prescribing. Some telehealth platforms accept recent lab work (within 90 days) from your primary care physician.

Required Labs Before Starting Retatrutide in South Carolina

Baseline laboratory testing is standard practice before initiating any incretin-based therapy. No prescriber should write a retatrutide prescription without reviewing recent labs.

Core Lab Panel

The following tests are considered standard of care for patients beginning weight management with an incretin-receptor agonist:

| Test | Purpose | |------|---------| | Comprehensive metabolic panel (CMP) | Kidney and liver function, electrolytes, fasting glucose | | HbA1c | Glycemic status over prior 2-3 months | | Lipid panel | Baseline cardiovascular risk stratification | | TSH | Thyroid function screening | | CBC | General health and anemia screening |

Additional Tests in Specific Populations

For patients with a history of pancreatitis, a serum lipase level may be ordered. Patients on concurrent medications metabolized by the liver may require a hepatic function panel. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends baseline metabolic screening before initiating any anti-obesity pharmacotherapy [5].

South Carolina has LabCorp and Quest Diagnostics locations in every major metro area (Charleston, Columbia, Greenville, Myrtle Beach). Most telehealth platforms will send a lab order to a draw site within 10 miles of your address.

How 503A Compounding Pharmacies Work in South Carolina

Since retatrutide does not yet have FDA approval, access comes through 503A compounding pharmacies that prepare the drug from bulk pharmaceutical-grade ingredients under a valid patient-specific prescription.

What Is a 503A Pharmacy?

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients based on a valid prescription [6]. These pharmacies operate under the oversight of the South Carolina Board of Pharmacy and must comply with United States Pharmacopeia (USP) chapter 797 standards for sterile compounding.

A 503A pharmacy is not a manufacturer. Each vial is prepared for a named patient after a prescriber sends the prescription directly. This is a legal and well-established pathway for accessing medications that are not commercially available, provided the pharmacy holds the appropriate state license.

Shipping and Delivery Within South Carolina

Most 503A pharmacies ship retatrutide in insulated cold-chain packaging with ice packs or gel packs to maintain peptide stability. Delivery to South Carolina addresses typically takes 5 to 10 business days from the date the pharmacy verifies the prescription. Some pharmacies offer expedited 2-day shipping for an additional fee.

Retatrutide must be stored at 2°C to 8°C (36°F to 46°F) upon arrival. Do not freeze. Once reconstituted (if applicable), use within the timeframe specified by the compounding pharmacy, which is typically 28 to 30 days.

Verifying Pharmacy Legitimacy

Before filling your prescription, confirm the compounding pharmacy is:

1. Licensed by the South Carolina Board of Pharmacy or its home state board
2. Compliant with USP 797 and USP 800 (if handling hazardous drugs)
3. Accredited by PCAB (Pharmacy Compounding Accreditation Board) or an equivalent body
4. Willing to provide a Certificate of Analysis (COA) for the active ingredient

A pharmacy that cannot produce a current COA should be avoided.

Cost and Insurance Coverage in South Carolina

Retatrutide is not covered by South Carolina Medicaid for chronic weight management. Since the drug is investigational, commercial insurers in the state (BlueCross BlueShield of South Carolina, Molina, Absolute Total Care) do not include it on their formularies.

Out-of-Pocket Pricing

Compounded retatrutide pricing varies by pharmacy and dose. Expect a range of $250 to $550 per month depending on dose tier and pharmacy markup. The dose titration schedule typically starts at a low dose (0.5 mg weekly) and increases over 8 to 12 weeks, so the first two months may cost less than maintenance months at higher doses.

How Pricing Compares

For context, branded tirzepatide (Zepbound) carries a list price of approximately $1,059.87 per month without insurance [7]. Compounded semaglutide typically runs $200 to $400 per month from 503A pharmacies. Compounded retatrutide falls in a similar range to compounded semaglutide, though prices fluctuate based on raw ingredient availability.

No manufacturer copay card or patient assistance program exists for retatrutide because it has not been commercially launched.

Prior Authorization: What South Carolina Patients Need to Know

Prior authorization (PA) for retatrutide is not currently applicable in the standard insurance sense because no insurer covers it. If a future FDA approval changes this, the PA process in South Carolina will likely mirror the requirements for other anti-obesity drugs.

Documentation That May Be Required Post-Approval

Based on existing PA requirements for tirzepatide and semaglutide in South Carolina, a PA request for a weight management drug typically requires:

• Documented BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Evidence of a failed trial of lifestyle modification (diet and exercise) for at least 3 to 6 months
• Current lab values (HbA1c, CMP, lipid panel)
• Prescriber's letter of medical necessity
• Step therapy documentation if the plan requires trial-and-failure of a cheaper agent first

The American Association of Clinical Endocrinology (AACE) 2023 obesity treatment algorithm recommends that insurers cover anti-obesity medications without step therapy requirements for patients with BMI ≥30 or BMI ≥27 with complications [8]. Most South Carolina commercial plans have not adopted this recommendation.

Retatrutide Dosing and Administration

Retatrutide is a once-weekly subcutaneous injection. Based on the phase 2 trial protocol, the titration schedule moved through escalating doses over several weeks [1].

Typical Titration Schedule

| Week | Dose | |------|------| | 1-4 | 0.5 mg weekly | | 5-8 | 1 mg weekly | | 9-12 | 2 mg weekly | | 13-16 | 4 mg weekly | | 17-20 | 8 mg weekly | | 21+ | 8 mg or 12 mg weekly (maintenance) |

Slow titration reduces gastrointestinal side effects. In the phase 2 trial, nausea occurred in 25.6% of participants in the 12 mg group compared to 8.9% in the placebo arm, but most cases resolved within the first 4 to 8 weeks of treatment [1].

Injection Sites and Technique

Inject into the abdomen, thigh, or upper arm. Rotate injection sites each week. Clean the site with an alcohol swab. Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly. Hold for 5 to 10 seconds before withdrawing.

Side Effects and Safety Monitoring

The phase 2 trial identified gastrointestinal symptoms as the primary adverse events. The data from 338 participants showed the following rates in the 12 mg group versus placebo [1]:

| Side Effect | 12 mg Group | Placebo | |-------------|-------------|---------| | Nausea | 25.6% | 8.9% | | Diarrhea | 22.0% | 8.9% | | Vomiting | 12.2% | 2.2% | | Decreased appetite | 14.6% | 2.2% | | Constipation | 12.2% | 4.4% |

When to Contact Your Prescriber

Call your prescriber if you experience persistent vomiting lasting more than 48 hours, signs of pancreatitis (severe abdominal pain radiating to the back), symptoms of gallbladder disease, or injection site reactions that worsen over time. The Endocrine Society recommends monitoring for signs of medullary thyroid carcinoma in patients on GLP-1 receptor agonists, though human data have not confirmed a causal link [5].

Follow-Up Schedule

Most telehealth providers require a follow-up visit at 4 to 6 weeks after initiation, then every 8 to 12 weeks during titration. Once on a stable maintenance dose, quarterly visits with repeat labs (CMP, HbA1c, lipid panel) are standard.

Transferring a Retatrutide Prescription to South Carolina

If you are relocating to South Carolina or splitting time between states, your existing retatrutide prescription can be transferred. The South Carolina Board of Pharmacy allows prescription transfers between licensed pharmacies under standard transfer rules.

For compounded medications, the process works slightly differently. Your new prescriber (licensed in SC) may need to write a new prescription rather than transfer the old one, because compounded prescriptions are patient-specific and pharmacy-specific. Contact your current compounding pharmacy and your new South Carolina provider to coordinate records, labs, and dosing history.

If your original prescriber holds a South Carolina license, they can continue prescribing via telehealth without a transfer.

What the Ongoing Phase 3 Program Means for South Carolina Access

Eli Lilly's phase 3 program for retatrutide includes multiple trials across obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). The TRIUMPH series of trials is enrolling thousands of participants. If phase 3 data replicate the phase 2 results, an FDA submission could follow within 12 to 18 months of trial completion [9].

FDA approval would open several new access pathways for South Carolina residents: commercial pharmacy dispensing, insurance formulary inclusion, manufacturer copay programs, and potential Medicaid coverage pending a state-level review.

Until then, 503A compounding remains the primary access route. South Carolina's telehealth-friendly regulatory environment and multiple compounding pharmacy shipping options make the state among the easier states for patients seeking early access.